Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) saw an uptick in trading volume on Thursday . 149,152 shares were traded during mid-day trading, an increase of 409% from the previous session's volume of 29,316 shares.The stock last traded at $5.27 and had previously closed at $5.36.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on IVA. Guggenheim boosted their price objective on shares of Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research report on Tuesday, September 2nd. Piper Sandler began coverage on shares of Inventiva in a research report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price objective for the company. HC Wainwright boosted their price objective on shares of Inventiva from $20.00 to $24.00 and gave the company a "buy" rating in a research report on Thursday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inventiva in a research report on Wednesday. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 price objective on shares of Inventiva in a research report on Tuesday, September 30th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.14.
Read Our Latest Stock Report on IVA
Inventiva Stock Up 3.2%
The business's 50 day moving average price is $5.10 and its two-hundred day moving average price is $3.92.
Institutional Trading of Inventiva
An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors own 19.06% of the company's stock.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
